EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Precigen's enterprise value is $277.79 Mil.
Precigen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $6.23 Mil. Therefore, Precigen's EV-to-Revenue for today is 44.63.
The historical rank and industry rank for Precigen's EV-to-Revenue or its related term are showing as below:
PGEN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 4.48 Med: 16.4 Max: 136.84
Current: 44.63
During the past 13 years, the highest EV-to-Revenue of Precigen was 136.84. The lowest was 4.48. And the median was 16.40.
PGEN's EV-to-Revenue is ranked worse than 77.5% of 1031
companies
in the Biotechnology industry
Industry Median: 7.6
vs PGEN: 44.63
As of today (2024-04-23), Precigen's stock price is $1.38.
Precigen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.03. Therefore, Precigen's PS Ratio for today is 53.08.
Precigen EV-to-Revenue Historical Data
The historical data trend for Precigen's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Precigen Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
32.89
19.35
59.47
11.59
44.63
Precigen Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
11.59
8.10
9.65
44.04
44.63
Competitive Comparison
For the Biotechnology subindustry, Precigen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Precigen's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Precigen's EV-to-Revenue falls into.
Precigen's current Enterprise Value is $277.79 Mil.
Precigen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen's share price for today is $1.38.
Precigen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Precigen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PGEN has been successfully added to your 